Cargando…
Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been re...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498562/ https://www.ncbi.nlm.nih.gov/pubmed/26167286 http://dx.doi.org/10.1186/s12878-015-0029-1 |
_version_ | 1782380640131350528 |
---|---|
author | Pálmason, Róbert Lindén, Ola Richter, Johan |
author_facet | Pálmason, Róbert Lindén, Ola Richter, Johan |
author_sort | Pálmason, Róbert |
collection | PubMed |
description | BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been reported to occur in association with Ruxolitinib. CASE PRESENTATION: We report a case of a 57 year old female with post-polycythemic myelofibrosis who was treated with Ruxolitinib. Approximately 9 weeks later she presented with a rapidly fatal, suspected EBV driven lymphoproliferative disorder in the CNS. CONCLUSIONS: Our report further underlines that patients treated with Ruxolitinib should be monitored closely for reactivations of opportunistic pathogens and viral infections. |
format | Online Article Text |
id | pubmed-4498562 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44985622015-07-11 Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib Pálmason, Róbert Lindén, Ola Richter, Johan BMC Hematol Case Report BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been reported to occur in association with Ruxolitinib. CASE PRESENTATION: We report a case of a 57 year old female with post-polycythemic myelofibrosis who was treated with Ruxolitinib. Approximately 9 weeks later she presented with a rapidly fatal, suspected EBV driven lymphoproliferative disorder in the CNS. CONCLUSIONS: Our report further underlines that patients treated with Ruxolitinib should be monitored closely for reactivations of opportunistic pathogens and viral infections. BioMed Central 2015-07-11 /pmc/articles/PMC4498562/ /pubmed/26167286 http://dx.doi.org/10.1186/s12878-015-0029-1 Text en © Pálmason et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Pálmason, Róbert Lindén, Ola Richter, Johan Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib |
title | Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib |
title_full | Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib |
title_fullStr | Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib |
title_full_unstemmed | Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib |
title_short | Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib |
title_sort | case-report: ebv driven lymphoproliferative disorder associated with ruxolitinib |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498562/ https://www.ncbi.nlm.nih.gov/pubmed/26167286 http://dx.doi.org/10.1186/s12878-015-0029-1 |
work_keys_str_mv | AT palmasonrobert casereportebvdrivenlymphoproliferativedisorderassociatedwithruxolitinib AT lindenola casereportebvdrivenlymphoproliferativedisorderassociatedwithruxolitinib AT richterjohan casereportebvdrivenlymphoproliferativedisorderassociatedwithruxolitinib |